1)Diener HC, et al:A preliminary, randomized, multicenter study comparing intravenous immunoglobulin, plasma exchange, and immune adsorption in Guillain-Barré syndrome. Eur Neurol 46:107-109, 2001
2)Hiraga A, et al:Recovery patterns and long term prognosis for axonal Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 76:719-722, 2005
3)日本神経治療学会・日本神経免疫合同神経免疫疾患治療ガイドライン委員会:ギラン・バレー症候群(GBS)治療ガイドライン.神経治療 20:194-200, 2003
4)Hadden RD, Hughes RA:Management of inflammatory neuropathies. J Neurosurg Psychiatry 74(suppl 2):ii9-ii14, 2003
5)van Koningsveld R, et al:Effect of methylpredonisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome:randomized trial. Lancet 363:192-196, 2004
6)Hughes RA, et al:Practice parameter;immunotherapy for Guillain-Barré syndrome:report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 61:736-740, 2003
7)Walgaard C, et al:Prediction of respiratory insufficiency in Guillain-Barré syndrome. Ann Neurol 67:781-787, 2010
8)van Koningsveld R, et al:A clinical prognostic scoring system for Guillain-Barré syndrome. Lancet Neurol 6:589-594, 2007
9)荻野美恵子,他:Guillain-Barre症候群の全国調査:第3次調査結果を含めた最終報告.免疫性神経疾患に関する調査研究班平成12年度研究報告書,pp 99-101, 2001